Study Published in Neurology Shows Chronic Epilepsy Associated with Marker of Cardiac Electrical Instability
The study in Neurology evaluated established markers of sudden cardiac death risk, T-wave alternans (TWA) and heart rate variability (HRV), in patients with chronic epilepsy compared to patients with newly diagnosed epilepsy.
“LifeSPARC is the new generation pump and controller for the venerable Tandem system – a small but powerful heart pump with a magnetic bearing, a low-profile controller and a highly simplified user interface. I believe many more patients will have access to this higher level of support for the first time,” said Dr. David Baran, System Director for Advanced Heart Failure Transplant and Mechanical Circulatory Support at Sentara Heart Hospital in Norfolk, Va.
5/3/19: New Clinical Data Emphasizing LivaNova Perceval Valve Durability: To Be Presented at the AATS
LivaNova PLC (NASDAQ:LIVN) has announced that new clinical data for its sutureless surgical aortic valve, Perceval®, will be unveiled at this year’s American Association for Thoracic Surgery (AATS) meeting.
Perceval Aortic Heart Valve Study North American Results Published in Journal of Thoracic and Cardiovascular Surgery
1/17/19: The multi-center, prospective, non-randomized, single-arm clinical trial included 300 patients from 18 U.S. centers.
6/14/18: “LivaNova is committed to innovation for mitral valve repair and replacement technology,” said Jason Richey, LivaNova’s President of North America. “Garnering FDA clearance for MEMO 4D addresses a real need and allows a broader patient population suffering from MR to be treated.”
LivaNova Receives CE Mark for VNS Therapy SenTiva Generator and Next-Generation Programming System for Treatment of Epilepsy
4/17/18: The SenTiva generator offers the smallest and lightest responsive therapy with a number of new advanced features for the treatment of DRE. SenTiva is the only device of its size to include the AutoStim Mode, also known as Seizure Response Mode, which is designed to detect seizures and automatically deliver an extra dose of therapy. The generator is also designed to collect and log events including a patient’s body position and heart rate fluctuations.
Bicarbon Aortic Valves Receive CE Mark for Expanded Use Labeling with Lower-Dose Blood Thinners in Low-Risk Patients
3/30/18: Reported by LivaNova.
Clinical Study to Evaluate Treatment Outcomes for Novel Microburst VNS Therapy System Launched: Reported by LivaNova
3/28/18: The study will examine the use of LivaNova’s new Microburst Vagus Nerve Stimulation Therapy® System.
12Page 1 of 2